Physician profile
Chien Shing Chen
NPI 1073542692
$15,137.69
in general payments reported to CMS, 2019-2025
19 companies · $5,387 in 2025
The $5,387 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22.78 · 2020: $320 · 2021: $135 · 2022: $6,745 · 2023: $1,721 · 2024: $808 · 2025: $5,387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,695 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,000 · Travel and Lodging: $1,989 · Food and Beverage: $1,231.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,695.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,000.00 |
| Travel and Lodging | $1,989.47 |
| Food and Beverage | $1,231.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $7,739.60 | 2022-2023 | |
| Avyxa Pharma, LLC | $4,495.77 | 2025 | |
| Beigene USA, INC. | $675.00 | 2024 | Brukinsa |
| Daiichi Sankyo INC. | $650.00 | 2025 | Vanflyta |
| Blueprint Medicines Corporation | $241.66 | 2022-2025 | |
| Genzyme Corporation | $208.80 | 2022-2024 | |
| Seagen INC. | $150.82 | 2020-2023 | Adcetris |
| Astellas Pharma US INC | $144.45 | 2023-2025 | Vyloy, Xospata |
| Eisai INC. | $124.99 | 2022 | |
| Janssen Biotech, INC. | $114.98 | 2021-2023 | Darzalex, Imbruvica |
| Pharmacyclics LLC, An Abbvie Company | $110.68 | 2020-2023 | Imbruvica, Epkinly |
| Spark Therapeutics, INC. | $92.01 | 2023 | |
| Merck Sharp & Dohme LLC | $87.79 | 2023-2024 | Keytruda, Lynparza, Welireg |
| Novartis Pharmaceuticals Corporation | $81.90 | 2019-2024 | |
| Pfizer INC. | $73.88 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Puma Biotechnology, INC. | $59.68 | 2020 | |
| Epizyme, INC. | $45.00 | 2021 | |
| Amgen INC. | $21.38 | 2020 | |
| Lilly USA, LLC | $19.30 | 2024 | Verzenio, Jaypirca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chien Shing Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.